

PROGRAM

7th International Conference on
**PHARMSCIENCE
RESEARCH &
DEVELOPMENT**

February 24-26, 2025 | HYBRID



DoubleTree by Hilton
San Francisco Airport
835 Airport Blvd
Burlingame, CA



EXHIBITOR

BI *.i.*

BRAND INSTITUTE

Where Great Brands Begin!®

 pharma-rnd@uniscigroup.net

 <https://pharmscience.unitedscientificgroup.org/>

DAY-01**IN-PERSON****ROOM: Sierra B**

Join the meeting

<https://us06web.zoom.us/j/88242968861?pwd=Z0oPjvVNF26lazBGBulKq3lugCSXYT.1>Meeting ID: **882 4296 8861**Passcode: **261953****08:00-09:00** Registrations & Badge Pickup**@ 37 NORTH Community Table****09:00-09:10** Welcome Speech

Keynote Presentations

Chair: **Yina Dong**, Assistant Professor, University of Pennsylvania, Philadelphia, PA**09:10-09:40****Rick G. Schnellmann**, Dean & Professor, University of Arizona College of Medicine, Tucson, AZ
Mitochondrial Biogenesis Drugs for Multiple Diseases**09:40-10:10****Wolfgang Sadee**, Chief Science Officer & Founder, Aether Therapeutics Inc., Austin, TX
Ligand-free Signaling of G Protein Coupled Receptors: Role in Opioid Dependence, Hyperalgesia, and Drug Craving - Promise for Treatments of Opioid Use Disorder

10:10-10:40 Coffee Break

@ Sierra Foyer**10:40-11:10****Donovan Yeates**, CEO & Founder, KAER Biotherapeutics, Escondido, CA
Delivering Critical Care Respiratory Therapeutics as High-concentration Aerosols Generated from Viscous and Complex Molecular Solutions**11:10-11:40****Tobias Funk**, VP, Technology Development, TripleRing Technologies, San Francisco, CA
Virtual Dose Mapping to Ensure Sterilization Outcomes Early in the Development Process**11:40-12:10****Priya Hays**, CEO, Hays Documentation Specialists, LLC, San Mateo, CA
The Transition from Targeted Therapies to Cancer Immunotherapies for Melanoma, Colorectal Cancer, Prostate Cancer and Renal Cell Carcinoma: Models for Therapy Development in Action**12:10-12:40****Bin Zhang**, Director, Icahn School of Medicine, Mount Sinai, NY
Precision Medicine for Alzheimer's Disease: Repurposing FDA-approved Drugs for Molecular Subtypes

Exhibitor Talk

12:40-13:00 **Pharmaceutical Lifecycle Naming**
Courtney Kilroy, Divisional President, Brand Institute, San Francisco, CA

13:00-14:00 Lunch

@ Courtyard

Oral Presentations

Drug: Discovery | Development | Delivery | Pre-clinical Research-1

Chair: Wei Li, Professor, Baylor College of Medicine, Houston, TX

14:00-14:20 **Ligandomics for Drug Target Discovery and a Novel Disease-targeted Anti-angiogenic Therapy**

Wei Li, Professor, Baylor College of Medicine, Houston, TX

14:20-14:40 **Drug Development in Oncology and Off Target Cardiac Effects**

Jean-Bernard Durand, Professor, MD Anderson Cancer Center, Houston, TX

14:40-15:00 **Expanding Assay Range to Accommodate a Monoclonal Antibody Therapeutic Quantification in Blood and Cerebrospinal Fluid**

Alejandro Rodriguez, Sr. Scientist, Genentech, San Francisco, CA

15:00-15:20 **Novel Mechanism for Treatment of SBMA (Kennedy's Disease) with a Dual-acting Androgen Receptor Inhibitor and Degradator**

Rajesh Krishnan, Chief Scientific Officer, Oncternal Therapeutics, Inc., San Diego, CA

15:20-15:40 **Delivery of Genes and Gene Editors by Programmable Milk Exosomes**

Janos Zempleni, Professor, University of Nebraska-Lincoln, Lincoln, NE

15:40-16:00 **Overcoming the Limitations of Current Docking Methods: New Strategies for Enhanced Accuracy**

Laszlo Fusti-Molnar, Founder, QuantumFuture Scientific Software LLC, Buda, TX

16:00-16:20 **A Peptide Derived from TIDIS Rescues Frataxin Deficiency and Mitochondrial Defects in FRDA Cellular Models**

Yina Dong, Assistant Professor, University of Pennsylvania, Philadelphia, PA

16:20-17:00 Posters & Networking Reception

@ Sierra Foyer

PRDP-01 **Optimization of Protein-ligand Molecular Docking Using Graph Convolutional Neural Networks: Predicting Binding Affinity and Posing**

Yolanda Marquez, Analytical Research Scientist, San Jose State University, San Jose, CA

PRDP-02 **Identifying Realistic Quantum Mechanics-based Conformations**

Laszlo Fusti-Molnar, Founder, QuantumFuture Scientific Software LLC, Buda, TX

PRDP-03 **Formulation and Optimization of Atorvastatin Calcium Cocrystals Applying Box-Behnken Design to Improve Drug Solubility and Dissolution**

Abdelazim Zaghoul, Associate Professor, Kuwait University, Kuwait

End of Day-1

Join the meeting

<https://us06web.zoom.us/j/88242968861?pwd=Z0oPjvVNF26lazBGBulKq3lugCSXYT.1>

Meeting ID: 882 4296 8861

Passcode: 261953

Oral Presentations

Pharmaceutical: Analysis | Chemistry | Manufacturing | Product Development

Chair: Stanislav Yefimov, Chemist Analyst, R&D, PharmetricLab, St. Petersburg, FL

09:00-09:20 **Seed Crystal Production in Space to Make New and Unique Crystals for Expansion**

Kenneth Savin, Chief Scientific Officer, RedWire, Jacksonville, FL

09:20-09:50 **Never Start from Scratch. Leverage your R&D Process Definition all the Way to Manufacturing**

Jacob Lee, Co-Founder and CEO, Genemod, Seattle, WA

Sergio Diaz, Product Marketing Manager, Emerson, Pflugerville, TX

09:50-10:10 **Tests for Endotoxin in Pharmaceutical Products. Inhibition of Limulus Amebocyte Lysate by Micelle-forming Substances, Phosphatidylcholine and Triton X-100**

Stanislav Yefimov, Chemist Analyst, R&D, PharmetricLab, St. Petersburg, FL

10:10-10:30 **Harnessing Quantum Chemistry and DFT Precision in Docking to Identify Low-toxicity Natural Products as IDO1 Inhibitors**

Laszlo Fusti-Molnar, Founder, QuantumFuture Scientific Software LLC, Buda, TX

10:30-10:50 Coffee Break

@ Sierra Foyer

Drug: Discovery | Development | Delivery | Artificial Intelligence in R&D | Preclinical Research-2

Chair: Maliha Zahid, Associate Professor, Mayo Clinic, Rochester, MN

10:50-11:10 **Revolutionizing Lead Clone Selection with Artificial Intelligence**

Ryan Holway, TetraScience, Boston, MA

11:10-11:30 **Glycopeptide Drugs Bridge the Gap Between 'Small Molecules' and 'Biologics'**

Robin Polt, Professor, The University of Arizona, Tucson, AZ

11:30-11:50 **Cardiac Targeting Peptide: From Discovery to Application**

Maliha Zahid, Associate Professor, Mayo Clinic, Rochester, MN

11:50-12:10 **UNC5B is a Driver of Metastasis in Pancreatic Ductal Adenocarcinoma (PDAC)**

Muhammad Sadeqi Nezhad, Cancer Researcher, Wilmot Cancer Center, Rochester, NY

12:10-12:30 **Revolutionizing Clinical Trial Monitoring with Augmented and Virtual Reality for Enhanced Data Visualization and Analytics**

Saurabh Das, Head, ADD Clinical Data Science, Tata Consultancy Services, India

12:30-12:50 **From Silos to Insights: Accelerating Drug Discovery with Chromatography Insights**

Rashi Takkar, TetraScience, Boston, MA

12:50-13:50 Lunch

@ Courtyard

Chair: Priya Hays, CEO, Hays Documentation Specialists, LLC, San Mateo, CA

- 13:50-14:10 **Molecular Targeting for Neuroblastoma**
Ruiwen Zhang, Professor, University of Houston College of Pharmacy, Houston, TX
- 14:10-14:30 **Advancing Therapeutics: Lessons from Drug Discovery for HCV, Malaria, and FXTAS**
Reem Olaby, Associate Professor, California Northstate University, Elk Grove, CA
- 14:30-14:50 **Aminoglycosides: Hearing Aids and Dialysis not Included. Side Effects of the Amazing Antibiotic**
Tyler Le, Future Otolaryngologist, American University of the Caribbean School of Medicine, Sint Maarten, NA
- 14:50-15:10 **Advancements in Ocular Fluorometry: Developing Systems for Precision Fluorescence Lifetime Measurements *In Vivo* and *Ex Vivo***
Sangly P. Srinivas, Professor, Indiana University, Bloomington, IN
- 15:10-15:30 **Accelerating Trustworthy Scientific Discovery with Next-generation Compute-in-memory Hardware**
George Williams, GSI Technology, Sunnyvale, CA
- 15:30-15:50 **Quantum Molecular Resonance Treatment for Dry Eye Disease (DED): Retrospective Non-randomized Study**
Ladislav Viktor Novacek, Faculty of Medicine, Charles University, Czech Republic

15:50-Coffee & End of Day-2

@ Sierra Foyer

Join the meeting

<https://us06web.zoom.us/j/88242968861?pwd=Z0oPjvVNF26lazBGBulKq3lugCSXYT.1>

Meeting ID: 882 4296 8861

Passcode: 261953

Oral Presentations

Pharmacology & Toxicology | Safety & Monitoring | Regulatory & HTA Review | Artificial Intelligence in R&D

Chair: Ruiwen Zhang, Professor, University of Houston College of Pharmacy, Houston, TX

08:50-09:10 **Next-generation MDM2 Inhibitors: *In Vitro* and *In Vivo* Anticancer Activities and Newly Discovered Effects on Cancer Metabolic Pathways**

Ruiwen Zhang, Professor, University of Houston College of Pharmacy, Houston, TX

09:10-09:30 **Enhancing Microphysiological Systems for Drug Development Using Stretchable Microelectrode Arrays**

Oliver Graudejus, Founder, BMSEED, Mesa, AZ

09:30-09:50 **AI and GenAI driven Insights from Medical and Scientific Literature: Streamlining and Accelerating Research**

Alejandra Guerchicoff, Industry Leader of Business & Development, Tata Consultancy Services, India

09:50-10:10 **Enhancing Clinical Trial Oversight Through Intelligent Automated Insights Generation**

Sushil Kumar Singh, Business Consultant, Tata Consultancy Services, India

10:10-10:30 **Efficacy and Safety Advantages of Disease-targeted Versus Non-targeted Anti-angiogenic Therapy**

Wei Li, Professor, Baylor College of Medicine, Houston, TX

10:30-10:50 **Demystifying Regulatory Guidance Using Generative and Conversational AI**

Saurabh Das, Head, ADD Clinical Data Science, Tata Consultancy Services, India

10:50-11:10 **Proteome Analysis, Genetic Characterization and Antibiotic Resistance Patterns of *Klebsiella pneumoniae* Clinical Isolates**

Saleh Mohammed Alamri, Prince Sultan Military Medical City, Saudi Arabia

11:10- Closing Remarks, Lunch & In-person Departures @ Courtyard

Virtual Oral Presentations

Timezone: Pacific Time (US and Canada)

11:25-11:30 Introduction

PharmSciences

Chair: Anna W. Sobanska, Professor, Medical University of Lodz, Poland

11:30-11:50 **Aggregation Induced by Therapeutic Proteins in Human Plasma and Blood: Pegfilgrastim and Filgrastim Case Studies**

Tudor Arvinte, CEO & President, Therapeomic Inc., Switzerland

11:50-12:10 **Artificial Intelligence and Molecular Modeling: Pioneering the Future of Precision Medicine**

Simone Ronsisvalle, Associate Professor, University of Catania, Italy

- 12:10-12:30 **Decentralized Clinical Trials: How Incorporate Patients Insights in the New Model**
Marta Garcia Manrique, CPO-R&D, Servier, Spain
- 12:30-12:50 **Unravelling the Role of Pain in GNAO1 Encephalopathy: The Potential of Molecular Dynamic for Individualized Therapy**
Federica Maria Sipala, Research Assistant, University of Catania, Italy
- 12:50-13:10 **Contemporary Views on the Blood-Brain Barrier Permeability of Organic Sunscreens – An *In-Silico* Study**
Anna W. Sobanska, Professor, Medical University of Lodz, Poland

13:10-13:20 Break

Virtual Keynote Presentations

13:20-13:50



Kenneth A. Jacobson, Senior Investigator, National Institutes of Health, Bethesda, MD
Action of Nucleosides and Other Modulators at Purinergic Drug Targets

13:50-14:20



Kenneth Wang, CEO, AtlasXomics Inc., New Haven, CT
Revolutionizing Spatial Epigenomic Analysis in Cancer

Virtual Oral Presentations

- 14:20-14:40 **A Novel Method to Optimize Drug Delivery for Parenteral Products Involving New Therapies and Unmet Needs**
Asmita Khanolkar, Sr. Director, SMC Ltd., Boston, MA
- 14:40-15:00 **A New Thoracic Aortic Aneurysm Rupture Mouse Model: A Consistent and Cost-Effective Tool for Pathogenesis Research and Drug Screening**
Li Li, Wayne State University, Detroit, MI
- 15:00-15:20 **Synthesis and Antibacterial Potential of New Spilanthol Derivatives**
Joaquin Gonzalez Marrero, Professor, Instituto Politécnico Nacional, Mexico
- 15:20-15:40 **Immunogenicity Risk Assessment of Biotherapeutic Attributes Using *In Vitro*, *In Vivo*, and Clinical Data**
Cathie Xiang, Principal Scientist, Amgen, Thousand Oaks, CA
- 15:40-16:00 **Evaluating the Impact of Biotherapeutic Aggregation Through *In Vitro* Reversibility Models**
Anthony Merlo, Amgen, Thousand Oaks, CA

16:00-Closing Remarks

EXHIBITOR



BRAND INSTITUTE

Where Great Brands Begin![®]

Brand Institute (BI), founded in 1993, is the global leader in brand name and identity development. We provide a broad portfolio of branding and naming-related services, including brand strategy, name development, trademark searches, market & safety research, and visual identity. In 2004 BI created its flagship regulatory subsidiary, Drug Safety Institute (DSI), to provide our pharmaceutical and biotech clients with industry-leading regulatory strategy, name safety, labeling and packaging solutions.

For more information: Website - www.brandinstitute.com/

For questions: contact@brandinstitute.com



BioPharmetriX: A Next-Gen BioPharma Summit

contact@biopharmetriX.com

We wish to see you at

Pharma R&D-2026

March 09-11, 2026 | Boston, MA



USG UNITED SCIENTIFIC GROUP (A non-profit organization)

8105, Suite 112, Rasor Blvd, Plano, TX 75024, USA

Ph: +1-469-854-2280/81 **Toll Free:** +1-844-395-4102

Email: pharma-rnd@uniscigroup.net

Web: <https://pharmscience.unitedscientificgroup.org/>